Document is current
Any future updates will be listed below
-
Authors
Goyal, Yogesh https://orcid.org/0000-0003-3502-6465
Busch, Gianna T. https://orcid.org/0000-0002-3328-0083
Pillai, Maalavika https://orcid.org/0000-0003-4661-1678
Li, Jingxin
Boe, Ryan H.
Grody, Emanuelle I.
Chelvanambi, Manoj https://orcid.org/0000-0003-2130-3118
Dardani, Ian P. https://orcid.org/0000-0002-0335-7422
Emert, Benjamin
Bodkin, Nicholas https://orcid.org/0000-0001-5090-9616
Braun, Jonas
Fingerman, Dylan
Kaur, Amanpreet
Jain, Naveen
Ravindran, Pavithran T.
Mellis, Ian A.
Kiani, Karun
Alicea, Gretchen M.
Fane, Mitchell E. https://orcid.org/0000-0001-6163-5753
Ahmed, Syeda Subia https://orcid.org/0000-0003-3002-2465
Li, Haiyin
Chen, Yeqing
Chai, Cedric https://orcid.org/0000-0002-4932-4941
Kaster, Jessica
Witt, Russell G.
Lazcano, Rossana
Ingram, Davis R.
Johnson, Sarah B. https://orcid.org/0000-0001-8936-0958
Wani, Khalida
Dunagin, Margaret C. https://orcid.org/0000-0002-8344-2570
Lazar, Alexander J.
Weeraratna, Ashani T.
Wargo, Jennifer A. https://orcid.org/0000-0003-3438-7576
Herlyn, Meenhard https://orcid.org/0000-0003-0839-0739
Raj, Arjun https://orcid.org/0000-0002-2915-6960
- License Information
-
More Information
Article History
Received: 30 December 2021
Accepted: 19 June 2023
First Online: 19 July 2023
Competing interests
: A.R. receives royalties related to Stellaris RNA FISH probes. Y.G. received consultancy fees from the Schmidt Science Fellows and the Rhodes Trust. A.J.L. reports financial relationships with AbbVie, Adaptimmune, AstraZeneca, Bain Capital, Bayer, Bio-AI Health, BMS, Caris, Deciphera, Foghorn Therapeutics, Gothams, GSK, Illumina, Invitae/Archer DX, Iterion Therapeutics, Merck, Novartis, Nucleai, OncoKB (MSKCC), Pfizer, Regeneron, Roche/Genentech, SpringWorks, Tempus and Thermo Fisher. J.A.W. is an inventor on US patent application no. PCT/US17/53.717 submitted by the University of Texas MD Anderson Cancer Center, which covers methods to enhance immune checkpoint blockade responses by modulating the microbiome. J.A.W. reports compensation for the speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune, Exelixis and Bristol Myers Squibb; and has served as a consultant and/or advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Micronoma, OSE therapeutics, Merck and Everimmune. J.A.W. receives stock options from Micronoma and OSE therapeutics. All other authors declare no competing interests.
